{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T15:11:27Z","timestamp":1759936287451,"version":"3.44.0"},"reference-count":34,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T00:00:00Z","timestamp":1632700800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100005564","name":"Gilead Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","journal-of-hepatology.eu","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Hepatology"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1016\/j.jhep.2021.09.017","type":"journal-article","created":{"date-parts":[[2021,9,27]],"date-time":"2021-09-27T15:20:06Z","timestamp":1632756006000},"page":"186-194","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"title":["Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments"],"prefix":"10.1016","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9158-1765","authenticated-orcid":false,"given":"Won-Mook","family":"Choi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1819-2464","authenticated-orcid":false,"given":"Terry Cheuk-Fung","family":"Yip","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1544-577X","authenticated-orcid":false,"given":"Young-Suk","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grace Lai-Hung","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3030-860X","authenticated-orcid":false,"given":"W. Ray","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jhep.2021.09.017_bib1","doi-asserted-by":"crossref","first-page":"1546","DOI":"10.1016\/S0140-6736(15)61412-X","article-title":"Estimations of worldwide prevalence of chronic hepatitis B virus infection: a systematic review of data published between 1965 and 2013","volume":"386","author":"Schweitzer","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.jhep.2021.09.017_bib2","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/S2468-1253(18)30056-6","article-title":"Global prevalence, treatment, and prevention of hepatitis B virus infection in 2016: a modelling study","volume":"3","author":"Razavi-Shearer","year":"2018","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib3","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1016\/j.jhep.2017.03.021","article-title":"EASL 2017 Clinical Practice Guidelines on the management of hepatitis B virus infection","volume":"67","author":"Lampertico","year":"2017","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib4","doi-asserted-by":"crossref","first-page":"1560","DOI":"10.1002\/hep.29800","article-title":"Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance","volume":"67","author":"Terrault","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.017_bib5","doi-asserted-by":"crossref","DOI":"10.14309\/ctg.0000000000000236","article-title":"Entecavir vs. Tenofovir in hepatocellular carcinoma prevention in chronic hepatitis B infection: a systematic review and meta-analysis","volume":"11","author":"Cheung","year":"2020","journal-title":"Clin Transl Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.017_bib6","article-title":"Effects of tenofovir vs. Entecavir on risk of hepatocellular carcinoma in patients with chronic HBV infection: a systematic review and meta-analysis","author":"Choi","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib7","article-title":"Comparative effectiveness of entecavir vs. Tenofovir for preventing hepatocellular carcinoma in patients with chronic hepatitis B: a systematic review and meta-analysis","author":"Dave","year":"2020","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.017_bib8","doi-asserted-by":"crossref","first-page":"1467","DOI":"10.1111\/jgh.15036","article-title":"Comparison of tenofovir versus entecavir on reducing incidence of hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"35","author":"Gu","year":"2020","journal-title":"J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib9","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1007\/s12072-019-10005-0","article-title":"Tenofovir versus entecavir in lowering the risk of hepatocellular carcinoma development in patients with chronic hepatitis B: a critical systematic review and meta-analysis","volume":"14","author":"Li","year":"2020","journal-title":"Hepatol Int"},{"key":"10.1016\/j.jhep.2021.09.017_bib10","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1159\/000507253","article-title":"Tenofovir treatment has lower risk of hepatocellular carcinoma than entecavir treatment in patients with chronic hepatitis B: a systematic review and meta-analysis","volume":"9","author":"Liu","year":"2020","journal-title":"Liver Cancer"},{"key":"10.1016\/j.jhep.2021.09.017_bib11","article-title":"Hepatocellular carcinoma incidence with tenofovir versus entecavir in chronic hepatitis B: a systematic review and meta-analysis","author":"Tseng","year":"2020","journal-title":"Lancet Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib12","doi-asserted-by":"crossref","first-page":"232","DOI":"10.5009\/gnl18546","article-title":"Nucleos(t)ide analogues for reducing hepatocellular carcinoma in chronic hepatitis B patients: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2020","journal-title":"Gut Liver"},{"key":"10.1016\/j.jhep.2021.09.017_bib13","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1186\/s12885-019-5735-9","article-title":"The effectiveness of TDF versus ETV on incidence of HCC in CHB patients: a meta analysis","volume":"19","author":"Zhang","year":"2019","journal-title":"BMC Cancer"},{"year":"2019","series-title":"Scientists rise up against statistical significance","author":"Amrhein","key":"10.1016\/j.jhep.2021.09.017_bib14"},{"key":"10.1016\/j.jhep.2021.09.017_bib15","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1007\/s10654-016-0149-3","article-title":"Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations","volume":"31","author":"Greenland","year":"2016","journal-title":"Eur J Epidemiol"},{"key":"10.1016\/j.jhep.2021.09.017_bib16","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1214\/aos\/1176345976","article-title":"Cox's regression model for counting processes: a large sample study","volume":"10","author":"Andersen","year":"1982","journal-title":"Ann Stat"},{"key":"10.1016\/j.jhep.2021.09.017_bib17","doi-asserted-by":"crossref","first-page":"E161","DOI":"10.1111\/hepr.12743","article-title":"Efficacy and safety of entecavir versus tenofovir treatment in chronic hepatitis B patients: a randomized controlled trial","volume":"47","author":"Sriprayoon","year":"2017","journal-title":"Hepatol Res"},{"key":"10.1016\/j.jhep.2021.09.017_bib18","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000013983","article-title":"Comparison of the long-term efficacy of tenofovir and entecavir in nucleos(t)ide analogue-naive HBeAg-positive patients with chronic hepatitis B: a large, multicentre, randomized controlled trials","volume":"98","author":"Cai","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.jhep.2021.09.017_bib19","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1001\/jamaoncol.2018.4070","article-title":"Risk of hepatocellular carcinoma in patients treated with entecavir vs. Tenofovir for chronic hepatitis B: a Korean nationwide cohort study","volume":"5","author":"Choi","year":"2019","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.jhep.2021.09.017_bib20","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1111\/jvh.12971","article-title":"Mortality, liver transplantation and hepatic complications in patients with treatment-naive chronic hepatitis B treated with entecavir vs. tenofovir","volume":"25","author":"Kim","year":"2018","journal-title":"J\u00a0Viral Hepat"},{"key":"10.1016\/j.jhep.2021.09.017_bib21","article-title":"Hepatitis B virus integrations promote local and distant oncogenic driver alterations in hepatocellular carcinoma","author":"P\u00e9neau","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.09.017_bib22","first-page":"3225","article-title":"Molecular characterization of HBV DNA integration in patients with hepatitis and hepatocellular carcinoma","volume":"9","author":"Yang","year":"2018","journal-title":"J\u00a0Cancer"},{"key":"10.1016\/j.jhep.2021.09.017_bib23","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1002\/hep.29320","article-title":"The risk of hepatocellular carcinoma decreases after the first 5 years of entecavir or tenofovir in Caucasians with chronic hepatitis B","volume":"66","author":"Papatheodoridis","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.jhep.2021.09.017_bib24","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.29537","article-title":"Impact of long-term tenofovir disoproxil fumarate on incidence of hepatocellular carcinoma in patients with chronic hepatitis B","volume":"121","author":"Kim","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.jhep.2021.09.017_bib25","doi-asserted-by":"crossref","first-page":"1297","DOI":"10.1038\/ajg.2016.257","article-title":"Lower observed hepatocellular carcinoma incidence in chronic hepatitis B patients treated with entecavir: results of the ENUMERATE study","volume":"111","author":"Ahn","year":"2016","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.017_bib26","doi-asserted-by":"crossref","first-page":"e125","DOI":"10.1038\/ctg.2017.51","article-title":"Seven-year treatment outcome of entecavir in a real-world cohort: effects on clinical parameters, HBsAg and HBcrAg levels","volume":"8","author":"Lam","year":"2017","journal-title":"Clin Translational Gastroenterol"},{"key":"10.1016\/j.jhep.2021.09.017_bib27","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1136\/gutjnl-2013-306247","article-title":"Serological and clinical outcomes of horizontally transmitted chronic hepatitis B infection in New Zealand M\u0101ori: results from a 28-year follow-up study","volume":"64","author":"Lim","year":"2015","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.09.017_bib28","doi-asserted-by":"crossref","first-page":"1037","DOI":"10.1016\/j.jhep.2020.06.011","article-title":"Similar risk of hepatocellular carcinoma during long-term entecavir or tenofovir therapy in Caucasian patients with chronic hepatitis B","volume":"73","author":"Papatheodoridis","year":"2020","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib29","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1159\/000086061","article-title":"Long-term results of lamivudine monotherapy in Korean patients with HBeAg-positive chronic hepatitis B: response and relapse rates, and factors related to durability of HBeAg seroconversion","volume":"48","author":"Yoon","year":"2005","journal-title":"Intervirology"},{"key":"10.1016\/j.jhep.2021.09.017_bib30","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/j.jhep.2019.03.028","article-title":"A\u00a0multicenter study of entecavir vs. tenofovir on prognosis of treatment-na\u00efve chronic hepatitis B in South Korea","volume":"71","author":"Kim","year":"2019","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib31","doi-asserted-by":"crossref","first-page":"2793","DOI":"10.1016\/j.cgh.2020.02.046","article-title":"No difference in incidence of hepatocellular carcinoma in patients with chronic hepatitis B virus infection treated with entecavir vs. Tenofovir","volume":"18","author":"Oh","year":"2020","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.jhep.2021.09.017_bib32","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1053\/j.gastro.2019.09.025","article-title":"Tenofovir is associated with lower risk of hepatocellular carcinoma than entecavir in patients with chronic HBV infection in China","volume":"158","author":"Yip","year":"2020","journal-title":"Gastroenterology"},{"key":"10.1016\/j.jhep.2021.09.017_bib33","article-title":"Hepatocellular carcinoma recurrence after direct-acting antiviral therapy: an individual patient data meta-analysis","author":"Sapena","year":"2021","journal-title":"Gut"},{"key":"10.1016\/j.jhep.2021.09.017_bib34","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/j.cgh.2020.04.045","article-title":"Hepatitis B core-related antigen to indicate high viral load: systematic review and meta-analysis of 10,397 individual participants","volume":"19","author":"Yoshida","year":"2021","journal-title":"Clin Gastroenterol Hepatol"}],"container-title":["Journal of Hepatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020791?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0168827821020791?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,29]],"date-time":"2025-09-29T19:43:17Z","timestamp":1759174997000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0168827821020791"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1]]},"references-count":34,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["S0168827821020791"],"URL":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.017","relation":{},"ISSN":["0168-8278"],"issn-type":[{"type":"print","value":"0168-8278"}],"subject":[],"published":{"date-parts":[[2022,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments","name":"articletitle","label":"Article Title"},{"value":"Journal of Hepatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jhep.2021.09.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 The Authors. Published by Elsevier B.V. on behalf of European Association for the Study of the Liver.","name":"copyright","label":"Copyright"}]}}